Literature DB >> 20064729

Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.

M Blanca Sánchez1, José L Herranz, Carlos Leno, Rosa Arteaga, Agustín Oterino, Elsa M Valdizán, José M Nicolás, Javier Adín, Juan A Armijo.   

Abstract

Epilepsy drug-resistance may depend on the metabolism of antiepileptic drugs (AEDs), transport to the epileptic focus and/or target sensitivity. Furthermore, drug response depends on multiple characteristics of the patient, the epilepsy, and the antiepileptic drugs used. We have investigated the association between polymorphisms related to antiepileptic drug metabolism (CYP2C9, CYP2C19, and UGT), transport (ABCB1), and targets (SCN1A) both in a crude analysis and after adjusting by clinical factors associated with drug-resistance, and stratifying by patient age or aetiology of epilepsy. Caucasian outpatients (N=289), children (N=80) and adolescent-adults (N=209), with idiopathic (N=69), cryptogenic (N=97) or symptomatic epilepsies (N=123) were selected when they had either drug-resistance (with at least four seizures over the previous year after treatment with more than three appropriate AEDs at appropriate doses) or drug responsiveness (without seizures for at least a year). Samples were genotyped by allelic discrimination using TaqMan probes. No significant association between polymorphisms and drug-resistance was found either in the crude analysis or in the adjusted analysis. However, adults with the ABCB1_3435TT or 2677TT genotypes had a lower risk of drug-resistance than those with the CC or the GG genotypes. Furthermore, patients with symptomatic epilepsies with the ABCB1_3435CT or TT genotypes had a lower risk of drug-resistance than those with the CC genotype. An opposite but insignificant tendency was found in children and in idiopathic epilepsies. Although replication studies will be needed to confirm our results, they suggest that stratification by patient age and by the aetiology of epilepsy could contribute to unmask the association between ABCB1 polymorphisms and drug-resistance of epilepsy. Copyright 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20064729     DOI: 10.1016/j.seizure.2009.12.004

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  23 in total

1.  Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.

Authors:  Ruchi Baghel; Sandeep Grover; Harpreet Kaur; Ajay Jajodia; Chitra Rawat; Ankit Srivastava; Suman Kushwaha; Rachna Agarwal; Sangeeta Sharma; Ritushree Kukreti
Journal:  CNS Neurosci Ther       Date:  2016-06-01       Impact factor: 5.243

2.  Association between two SCN1A polymorphisms and resistance to sodium channel blocking AEDs: a meta-analysis.

Authors:  Yi Bao; Xinzhu Liu; Zheng Xiao
Journal:  Neurol Sci       Date:  2018-03-26       Impact factor: 3.307

3.  SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.

Authors:  Lihong Shi; Miaomiao Zhu; Huilan Li; Zhipeng Wen; Xiaoping Chen; Jia Luo; Cong Lin; Zanling Zhang
Journal:  Eur J Clin Pharmacol       Date:  2019-01-28       Impact factor: 2.953

Review 4.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.

Authors:  Stefan Wolking; Elke Schaeffeler; Holger Lerche; Matthias Schwab; Anne T Nies
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

5.  Associations between the C3435T polymorphism of the ABCB1 gene and drug resistance in epilepsy: a meta-analysis.

Authors:  Wei-Ping Lv; Ren-Feng Han; Zhi-Rong Shu
Journal:  Int J Clin Exp Med       Date:  2014-11-15

6.  Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy.

Authors:  Tracy A Glauser; Katherine Holland; Valerie P O'Brien; Mehdi Keddache; Lisa J Martin; Peggy O Clark; Avital Cnaan; Dennis Dlugos; Deborah G Hirtz; Shlomo Shinnar; Gregory Grabowski
Journal:  Ann Neurol       Date:  2017-03       Impact factor: 10.422

Review 7.  Gene polymorphisms and their role in epilepsy treatment and prognosis.

Authors:  Ortrud K Steinlein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-16       Impact factor: 3.000

8.  Metabolic profiling of praziquantel enantiomers.

Authors:  Haina Wang; Zhong-Ze Fang; Yang Zheng; Kun Zhou; Changyan Hu; Kristopher W Krausz; Dequn Sun; Jeffrey R Idle; Frank J Gonzalez
Journal:  Biochem Pharmacol       Date:  2014-05-10       Impact factor: 5.858

Review 9.  Pharmacogenetics of chronic pain and its treatment.

Authors:  Svatopluk Světlík; Karolína Hronová; Hana Bakhouche; Olga Matoušková; Ondřej Slanař
Journal:  Mediators Inflamm       Date:  2013-05-20       Impact factor: 4.711

10.  Association of ABCB1 gene polymorphism (C1236T and C3435T) with refractory epilepsy in Iraqi patients.

Authors:  Khalid S Salih; Farqad B Hamdan; Qasim S Al-Mayah; Akram M Al-Mahdawi
Journal:  Mol Biol Rep       Date:  2020-05-27       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.